Similar Datasets
Project description:Expression Data from DMSO or honokiol treated THP-1 and U-937 cells
| PRJNA822937 | ENA
Project description:The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate ester of honokiol. In addition, we synthesized a novel fluorinated honokiol analog, bis-trifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane (hexafluoro). Both compounds exhibited activity against A375 melanoma in vivo, but honokiol DCA was more active. Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental LM36. Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization. Honokiol DCA may act in vemurafenib resistant melanomas to increase both respiration and reactive oxygen generation, leading to activity against aggressive melanoma in vivo. Tumors from animals treated with control vehicle, honokiol DCA, and hexafluoro were harvested and snapped-frozen in liquid nitrogen until RNA Extraction. RNA extraction was performed according to the Qiagen RNeasy kit. RNA samples were then submitted to Emory Universityâs Intergrated Genomics Core for RNA quality analysis and gene expression assay. Gene expression analysis was performed using an Illumina HumanHT-12 v3 Expression Bead Chip and Gene Expression Module of Illuminaâs GenomeStudio Software package (v2011.1, Illumina).
2016-01-20 | E-GEOD-76956 | biostudies-arrayexpress
Project description:The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of these aggressive melanomas. Honokiol is a small molecule compound derived from Magnolia grandiflora that has activity against solid tumors and hematopoietic neoplasms. In order to increase the lipophilicity of honokiol, we have synthesized honokiol DCA, the dichloroacetate ester of honokiol. In addition, we synthesized a novel fluorinated honokiol analog, bis-trifluoromethyl-bis-(4-hydroxy-3-allylphenyl) methane (hexafluoro). Both compounds exhibited activity against A375 melanoma in vivo, but honokiol DCA was more active. Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo. We then examined its effect against a pair of melanomas, LM36 and LM36R, in which LM36R differs from LM36 in that LM36R has acquired vemurafenib resistance. Honokiol DCA demonstrated in vivo activity against LM36R (vemurafenib resistant) but not against parental LM36. Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization. Honokiol DCA may act in vemurafenib resistant melanomas to increase both respiration and reactive oxygen generation, leading to activity against aggressive melanoma in vivo.
2016-01-20 | GSE76956 | GEO
Project description:Escherichia coli strain:937 | isolate:937 Genome sequencing
| PRJNA977425 | ENA
Project description:To globally evaluate transcriptome in THP-1 and decitabine-resistant THP-1 cells treated by decitabine, cells were treated with the IC90 dose of decitabine until 90% cell death was reached, then cultured in decitabine-free medium until confluence, followed by another round of decitabine treatment and the treatment cycles were repeated for 3 months to generate decitabine-resistant THP-1 cells. We then performed gene expression profiling analysis using data obtained from RNA-seq of THP-1 or decitabine-resistant THP-1 cells treated with or without decitabine.
2025-06-28 | GSE269185 | GEO
Project description:Honokiol (HNK), one of the main medicinal components in Magnolia officinalis, possesses antimicrobial activity against a variety of pathogenic bacteria and fungi.S. cerevisiae is a model eukaryote used for investigating the cellular and molecular mechanisms of anti-fungal drugs. To explore the molecular mechanism of its anti-fungal activity, we determined the effects of HNK on the mRNA expression profile of Saccharomyces cerevisiae using a DNA microarray approach.
2017-05-22 | GSE94945 | GEO
Project description:It is unclear how nanosecond electrical pulses affect gene expression. We used microarrays to identify how cells respond to this specific type of stress U-937 cells were exposed to 100, 10 nanosecond duration pulses at 150 kV/cm. Gene expression was analyzed 4 hrs post exposure
2016-02-16 | E-GEOD-77908 | biostudies-arrayexpress
Project description:Streptomyces sp. NTK 937 Genome sequencing and assembly
| PRJNA244371 | ENA
Project description:Escherichia coli K1 strain:937 Genome sequencing
| PRJNA257959 | ENA
Project description:It is well known that HIV-1 does not infect neurons, however neurons are the most affected cells by the virus. Several studies linked the deregulation of neuronal transcriptional machinery to single HIV proteins, however the impact of the all the viral proteins on neurons remain unknown. In here we infected U-937 cells with JR-FL strain of HIV-1. 21 days later, the supernatants were collected and subjected to p24ELISA to measure the level of the virus. Supernatant was then added to SH-SY5Y cells in culture for 24hrs. The cells were then collected, RNA isolated and subjected to gene array analysis. Human neuronal cell line, SH-SY5Y were chosen to examine the impact of HIV-1 supernatant prepared from U-937 infected cells on gene expression in neuronal cells.
2012-12-07 | E-GEOD-42615 | biostudies-arrayexpress